M yocardial ischemia represents a major health problem in Western countries. Current therapeutic interventions focus mainly on early and persistent coronary reperfusion, and additional pharmacological strategies to increase resistance to myocardial ischemia are currently areas of intense investigation. A powerful strategy for cardioprotection would be to recapitulate the consequences of ischemic preconditioning (IP), in which short and repeated episodes of ischemia and reperfusion before myocardial infarction result in attenuation of infarct size. Despite multiple attempts to identify the underlying molecular mechanisms, pharmacological strategies using such pathways have yet to be further defined and introduced into clinical practice.
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Recent studies have implicated extracellular adenosine in the modulation of acute inflammation and tissue protection, particularly during conditions of hypoxia. [1] [2] [3] [4] [5] Extracellular adenosine is derived mainly via phosphohydrolysis of AMP. Ecto-5Ј-nucleotidase (CD73), a ubiquitously expressed glycosyl phosphatidylinositol-anchored ectoenzyme, is the pacemaker of this reaction. 6 Because of its transcriptional induction by hypoxia, 6, 7 CD73-dependent adenosine generation is particularly prominent during conditions of limited oxygen availability, as may occur during myocardial ischemia. 2 Nevertheless, pharmacological studies on the role of CD73-dependent adenosine generation in cardioprotection during ischemia and reperfusion have yielded conflicting results. 8, 9 Extracellular adenosine produced by CD73 can signal through any of 4 extracellular adenosine receptors (A 1 AR, A 2A AR, A 2B AR, or A 3 AR). All 4 ARs have been associated with tissue protection in a variety of physiological settings. 1, 10, 11 Although all 4 ARs are expressed in cardiac tissues, 12 the contribution of individual receptors to cardioprotection from ischemia and reperfusion remains controversial 13, 14 and may in part be related to a lack of studies in which all 4 AR gene-targeted mice are subjected to the same IP protocol in parallel.
To elucidate the contribution of CD73-dependent adenosine generation and to clarify the role of individual ARs in cardioprotection during IP, we used a recently described model of murine in situ preconditioning incorporating a hanging weight system for intermittent coronary artery occlusion, thus minimizing the variability associated with knotbased coronary occlusion systems. 15 In the present study, we applied this model in mice gene targeted for cd73 or each individual AR. In addition, we used specific pharmacological adenosine therapeutics to confirm the findings from genetargeted mice. We found a critical role for CD73-dependent adenosine production and, surprisingly, signaling through the A 2B AR for cardioprotection by IP. Consistent with these findings, we observed a significant reduction in infarct size after acute ischemia by treatment with soluble 5Ј-nucleotidase or a specific A 2B AR agonist.
Methods

Mice
All animal protocols were in accordance with the German guidelines for use of living animals and were approved by the Institutional Animal Care and Use Committee of the Tübingen University Hospital and the Regierungspräsidium Tübingen. C57BL/6J mice were obtained from Charles River Laboratories (Sulzfeld, Germany). Mice deficient in cd73, A 1A AR, or A 3 AR on the C57BL/6 strain or in A 2A AR on the CD1 strain have been described previously. 6,16 -18 A 2B AR-deficient mice were generated by Deltagen, Inc (San Carlos, Calif).
Murine Model for Cardiac IP
In pharmacological studies, age-, gender-and weight-matched C57BL/6J mice were used. Cardiac IP was performed using a hanging weight system as described previously. 15 
Heart Enzyme Measurement
Blood was collected by central venous puncture for troponin I (cTnI) measurements using a quantitative rapid cTnI assay (Life Diagnostics, Inc, West Chester, Pa).
Transcriptional Analysis
To assess the influence of IP on cd73, A 1 AR, A 2A AR, A 2B AR, and A 3 AR transcript levels, 4 cycles of IP (5 minutes of ischemia, 5 minutes of reperfusion) were performed, the area at risk (AAR) was delineated by Evan's blue staining, and excised and transcript levels were determined (see the expanded Materials and Methods section in the online Data Supplement).
Immunoblotting Experiments
In subsets of experiments, we determined CD73 and adenosine A 2B AR protein content from the AAR as described previously. 15 
Ecto-5-Nucleotidase Enzyme Assays
Ecto-5Ј-nucleotidase enzyme activity was evaluated as described previously. 6 
Adenosine Measurements
Tissue adenosine and AMP levels were determined via highperformance liquid chromatography as described previously. 19 
Neutrophil Depletion
In selected experiments, neutrophil depletion was achieved with an anti-Gr-1 monoclonal antibody (BD Biosciences/Pharmingen, San Jose, Calif) as described previously. 20 
Data Analysis
Data were compared by 2-factor ANOVA or Student t test where appropriate. Values are expressed as meanϮSD from 4 to 6 animals per condition. For analysis of changes in transcript, data are expressed as meanϮSEM, and the Dunnett test was used (PϽ0.05 was considered statistically significant).
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Cardiac CD73 Is Induced by IP
Because previous studies demonstrated tissue protection by extracellular adenosine generated via hypoxia-inducible CD73, 2,7,11 we hypothesized that CD73-dependent adenosine generation also may be critical for cardioprotection during IP. Therefore, we investigated the transcriptional consequences of cardiac IP on CD73 expression and function using a previously described model of cardiac IP ( Figure 1A ). 15 Briefly, we performed 4 cycles of intermittent left coronary artery occlusion and reperfusion (5 minutes of ischemia, 5 minutes of reperfusion) in an open-chest in situ model of IP using a hanging weight system, which causes virtually no surgical tissue trauma during IP. The so-called AAR (myocardial tissue supplied by the intermittently occluded coronary artery) was identified using retrograde injection of Evan's blue and was compared with myocardial tissue from unpreconditioned matched littermates. To define the transcriptional effects of IP, preconditioned myocardial tissue was harvested at indicated time points after IP treatment and used for real-time reverse-transcriptase polymerase chain reaction. We found a robust induction of cd73 mRNA (eg, 90 minutes after cardiac IP; 14.5Ϯ2.7-fold; PϽ0.01) ( Figure  1B) . Similarly, Western blots of the AAR confirmed CD73 protein induction after IP ( Figure 1C ). Immunohistological staining of the AAR and imaging via confocal laser scanning microscopy confirmed the strong induction of CD73 protein ( Figure 1D ). Conventional microscopy confirmed CD73 induction on both cardiomyocytes and endothelia within the AAR 90 minutes after IP ( Figure 1E ), whereas isotype controls were negative (Data Supplement Figure I ). We also demonstrated functional induction of CD73 by IP by measuring ecto-5Ј-nucleotidase enzyme activity ( Figure 1F ). 6 Taken together, these data provide strong evidence that CD73 is induced within the AAR by cardiac IP.
CD73 Inhibition Attenuates Cardioprotection by IP
We next pursued the functional contribution of CD73 to cardioprotection by IP by treating mice with an intra-arterial infusion of the specific CD73-inhibitor adenosine 5Ј-(␣,␤-methylene) diphosphate (APCP; 40 mg · kg Ϫ1 · h Ϫ1 ) or vehicle control before cardiac IP and/or ischemia. As shown in Figure  2A , this resulted in a 3-fold reduction in cardiac CD73 enzyme activity. Similarly, AMP-induced bradycardia was significantly attenuated in APCP-treated animals (heart rate reduction from 480 to 360 bpm versus from 480 to 120 bpm in control mice; PϽ0.0001; Figure 2B ). After having shown effective inhibition of cardiac CD73 enzyme activity with APCP, we investigated the role of CD73 in cardioprotection by IP by subjecting mice to 60 minutes of left coronary artery occlusion, followed by 2 hours of reperfusion with or without prior IP (4 cycles; 5 minutes of ischemia, 5 of minutes reperfusion) and with or without APCP. All mice survived this experiment. Heart rate and blood pressure did not differ between APCP-treated and untreated mice. To assess myocardial tissue damage, we measured plasma levels of a previously described marker for murine myocardial ischemia, cTnI. 21 Consistent with previous studies, 15 plasma cTnI concentrations were attenuated by IP ( Figure 2C ). However, Age-, sex-, and weight-matched mice were anesthetized with pentobarbital and mechanically ventilated. In situ IP consisting of 4 cycles of ischemia/reperfusion (5 minutes each), followed by indicated times of reperfusion, was performed using a hanging weight system for atraumatic occlusion of the left coronary artery. B, cd73 mRNA is induced by IP. At the indicated times, the AAR was excised, total RNA was isolated, and cd73 mRNA was quantified by realtime reverse-transcriptase polymerase chain reaction. Data were calculated relative to ␤-actin and are expressed as fold change vs control (no IP)ϮSD (nϭ6; *PϽ0.05). C, CD73 protein is induced by IP as shown by Western blotting. Tissue from the AAR was excised, flash-frozen, and lysed, and proteins were resolved by SDS-PAGE and transferred to nitrocellulose. Membranes were probed with an anti-CD73 antibody. One representative experiment of 3 is shown. The same blot was probed for ␤-actin as a control for protein loading. D, CD73 protein is induced by IP as shown by immunohistochemistry. Animals were killed 90 minutes after IP as described above, and tissue from the AAR was sectioned, stained with anti-CD73 antibodies, and visualized with confocal laser scanning microscopy. Tissue from a perfused but unpreconditioned wild-type mouse served as control. Staining of wild-type cardiac tissue with secondary antibody alone is shown in top (neg). E, Comparison of immunoreactivity for CD73 on cardiomyocytes (arrow) and endothelial cells (*) from the AAR of controls (ϪIP) and mice treated with IP (90 minutes, ϩIP; magnification ϫ1000). F, CD73 enzyme activity is induced by IP. Cardiac tissue from the AAR was excised after IP treatment and flash-frozen, and extracts were prepared as described in Methods. 5Ј-Nucleotidase enzyme activity was evaluated by measuring the conversion of 
Cardioprotection by IP Is Abolished in
To further demonstrate the importance of CD73 in the cardioprotective effects of IP, we next studied mice with targeted deletion of the cd73 gene. 6 We first confirmed the absence of CD73 enzyme activity in the cardiac tissue of these mice ( Figure 3A) . Similarly, AMP-induced bradycardia was significantly attenuated in cd73 Ϫ/Ϫ mice compared with littermates ( Figure 3B ). We next performed IP in cd73 Ϫ/Ϫ mice and littermate controls. In striking contrast to results with wild-type mice, infarct sizes and increased plasma cTnI levels caused by 60 minutes of ischemia were not attenuated by IP in cd73 Ϫ/Ϫ mice ( Figure 3C and 3D). The protection afforded by IP persisted for at least 90 minutes after the completion of IP in wild-type mice but was abolished in cd73 Ϫ/Ϫ mice (Data Supplement Figure II) . Moreover, cd73 Ϫ/Ϫ mice had significantly bigger infarcts after 60 minutes of ischemia without IP compared with controls.
To suggest that the absence of cardioprotection by IP in cd73 Ϫ/Ϫ mice reflects a lack of extracellular adenosine, we reconstituted extracellular adenosine levels via intra-arterial infusion (200 L/h, adenosine 8 mg/mL) with a dose we previously determined not to induce hypotension or bradycardia (data not shown). Indeed ( Figure 3E ), this treatment resulted in partial reconstitution of cardioprotection by IP in cd73 Ϫ/Ϫ mice. Similar treatment of wild-type mice resulted in attenuation of infarct sizes only after IP, suggesting additional mechanisms (eg, increases in AR-mediated signaling by IP).
In additional experiments, we reconstituted cd73 Ϫ/Ϫ mice via intra-arterial soluble 5Ј-nucleotidase (1 U 5Ј-nucleotidase from Crotalus atrox venom). As shown in Figure 3F , 5Ј-nucleotidase treatment was associated with an almost complete reconstitution of a wild-type phenotype. Moreover, 5Ј-nucleotidase treatment was associated with a significant reduction in infarct size in wild-type animals ( Figure 3F ). Taken together, these data reveal for the first time genetic evidence for CD73-dependent cardioprotection by IP. Furthermore, we show treatment with soluble 5Ј-nucleotidase as a potential novel therapy during acute myocardial ischemia. Ϫ/Ϫ mice. Wild-type or cd73 Ϫ/Ϫ mice were treated with a bolus of AMP (50 L, 8 mg/mL) via a carotid artery catheter, and heart rate was measured via surface ECG. Bradycardia is expressed as the percentage change in heart rate. C, IP-induced reductions in infarct size are abolished in cd73 Ϫ/Ϫ mice. cd73 ϩ/ϩ and cd73 Ϫ/Ϫ mice were subjected to in situ preconditioning with 4 cycles of IP (5 minutes of ischemia, 5 minutes of reperfusion), followed by 60 minutes of ischemia, and were killed after 2 hours of reperfusion. Infarct sizes were measured by double staining with Evan's blue and TTC and are expressed as the percent of the AAR that underwent infarction (meanϮSD; nϭ6). D, IP-induced reductions in plasma troponin I levels are absent in cd73 Ϫ/Ϫ mice. Troponin I plasma levels were measured in cd73 ϩ/ϩ or cd73 Ϫ/Ϫ mice with and without IP before 60 minutes of ischemia and 2 hours of reperfusion. E, Treatment with adenosine improves cardioprotection by IP in cd73 Ϫ/Ϫ and cd73 ϩ/ϩ mice. cd73 Ϫ/Ϫ mice and matched littermate controls received an intra-arterial infusion with adenosine (200 L/h, 8 mg/mL). After 60 minutes, IP was performed, followed by 60 minutes of ischemia and 2 hours of reperfusion. Infarct size was determined by Evan's blue and TTC double staining. F, Treatment with soluble 5Ј-nucleotidase improves cardioprotection by IP in cd73 Ϫ/Ϫ and cd73 ϩ/ϩ mice. cd73 Ϫ/Ϫ mice matched littermate controls received 1 U intra-arterial soluble 5Ј-nucleotidase purified from C atrox venom 60 minutes before IP, followed by 60 minutes of ischemia and 2 hours of reperfusion, and compared with controls without IP treatment (ϩ/ϪIP). Infarct size was determined by Evan's blue and TTC double staining and is expressed as the percent of the AAR that underwent infarction (meanϮSD; nϭ6).
Increases in Cardiac Adenosine
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Cardioprotection by CD73 and A 2B ARprevious studies, 9 cardiac adenosine and AMP concentrations measured within the AAR immediately after IP ( Figure 4) were increased, suggesting that AMP is produced during IP treatment and leaks from the preconditioned tissue. In contrast, cd73 Ϫ/Ϫ mice exhibited attenuated adenosine levels in conjunction with increased AMP concentrations after IP treatment. Taken together, these studies demonstrate that CD73 functions to increase myocardial adenosine during preconditioning.
Cardiac IP Is Associated With Selective Induction of the A2BAR
After having demonstrated that extracellular adenosine generation via CD73 is crucial for IP, we next investigated transcriptional consequences of cardiac IP on expressional levels of all 4 ARs (Figure 5A through 5D ). These studies revealed selective induction of the A 2B AR transcript with cardiac IP (14-fold induction 90 minutes after IP; PϽ0.0001). In contrast, mRNA levels for A 1 AR and A 3 AR remained unchanged, whereas that for A 2A AR was significantly repressed. Similarly, immunohistochemistry confirmed the induction of A 2B AR protein on cardiomyocytes and endomuscular capillaries 90 minutes after IP ( Figure 5E ). To show that increases in A 2B AR expression are not merely caused by increases in A 2B AR ϩ inflammatory cells penetrating the ischemic area during reperfusion, we demonstrated via Western blot that A 2B AR protein was still induced after neutrophil depletion ( Figure 5F ). Furthermore, staining of cardiac tissues after IP treatment showed only scattered neutrophils (Data Supplement Figure III) . Taken together, these data suggest selective and robust induction of A 2B AR in cardiac tissues by IP. Figure 6A ). Because measurements of heart rate and blood pressure did not reveal any differences between gene-targeted mice (Data Supplement  Tables I and II) , it seems unlikely that abolished cardioprotection could be explained by hemodynamic alterations. Taken together, these data provide the first genetic evidence for a pivotal role of A 2B AR in cardioprotection by IP. To confirm these findings using a pharmacological approach, we used the highly specific, water-soluble A 2B AR antagonist PSB1115. 22 As shown in Figure 6D , intra-arterial treatment with PSB1115 (5 mg · kg Ϫ1 · h Ϫ1 ) abolished infarct size attenuation by IP, thus confirming our findings in A 2B AR Ϫ/Ϫ mice. To demonstrate that PSB1115 does not exhibit its anticardioprotective effects through blockade of A 1 AR, we also treated A 1 AR Ϫ/Ϫ mice with PSB1115. As shown in Figure  6E , cardioprotection by IP in A 1 AR Ϫ/Ϫ mice was attenuated by specific blockade of A 2B AR. Taken together, these studies provide genetic and pharmacological evidence for a role of A 2B AR in cardioprotection by IP.
IP Is Abolished in
A 2B AR Agonist Treatment Results in Smaller Infarcts During Acute Myocardial Ischemia
Next, we pursued a potential therapeutic role of a novel specific A 2B AR agonist (BAY 60 -6583). The chemical structure and selectivity are displayed in Figure 7A and 7B, and functional in vivo evidence in shown in Data Supplement Figure IV . Wild-type, but not A 2B AR Ϫ/Ϫ , mice treated with a single bolus of intra-arterial BAY 60 -6583 (10 g/kg body weight) over 40 minutes before 60 minutes of myocardial ischemia exhibited a significant attenuation of infarct size ( Figure 7C and 7D) . These studies confirm the specificity of the cardioprotective effects of BAY 60 -6583 through A 2B AR signaling and provide strong rationale for therapeutically targeting A 2B AR during myocardial ischemia.
Discussion
In the present study, we pursued the contribution of extracellular adenosine production and signaling to cardioprotection by IP. Transcriptional profiling of preconditioned cardiac tissue revealed a prominent induction of cd73 and A 2B AR mRNA. Pharmacological inhibition or targeted gene deletion of cd73 abolished the cardioprotective effects of in situ IP. Similarly, IP was abrogated in mice gene targeted for A 2B AR, whereas mice deficient in each of the other ARs (A 1 AR, A 2A AR, A 3 AR) showed reduced infarct sizes after IP. Moreover, soluble 5Ј-nucleotidase or A 2B AR agonist treatment mimicked cardioprotection by IP because it was associated with significant attenuation of myocardial infarct sizes after ischemia. Taken together, these studies suggest manipulation of CD73 enzyme activity to increase extracellular adenosine concentrations and signaling through A 2B AR as therapeutic strategies for the treatment of coronary artery disease.
Previous studies on adaptation to hypoxia have revealed coordinated transcriptional induction of cd73 and A 2B AR by hypoxia inducible factor (HIF)-1. In fact, hypoxia exposure of intestinal epithelia (Caco2 cells) or human endothelia (HMEC-1) was associated with robust induction of cd73 transcript, protein, and function. 2, 7 Furthermore, hypoxia exposure of cd73 Ϫ/Ϫ mice resulted in dramatic increases in vascular leakage, suggesting a functional role of CD73-dependent adenosine production in maintaining vascular barrier function during limited oxygen availability. Moreover, examination of the cd73 gene promoter identified a site for HIF-1␣ binding, and further studies with promoter constructs and site-directed mutagenesis of the HIF-1␣ binding site confirmed an HIF-1␣-dependent regulatory pathway for cd73 induction. 7 Similarly, hypoxia exposure of endothelia (HMEC-1) resulted in a selective induction of A 2B AR mRNA. 2 Further studies examining HIF-1␣ DNA binding and HIF-1␣ loss and gain of function confirmed strong dependence of A 2B AR induction by HIF-1␣ in vitro and in vivo. 23 Therefore, it is not surprising that repeated episodes of ischemia/hypoxia as used during cardiac IP resulted in coordinated transcriptional induction of cd73 and A 2B AR mRNA. In addition, mice with normoxic stabilization of HIF-1␣ by in vivo siRNA knockdown of HIF-1␣-prolyl-4-hydroxylase-2 showed cardioprotection from ischemia and reperfusion. 24 Therefore, it is likely that the observed cardioprotective effects of CD73-dependent adenosine production and signaling through the A 2B AR during cardiac IP are related to a transcriptional response coordinated by HIF-1␣.
Previous studies on the contribution of AR signaling to cardioprotection during IP have revealed conflicting results 13 In contrast, other studies found an absence of the infarct sizelimiting effects of IP in A 1 AR gene-targeted mice, whereas A 1 AR-overexpressing mice were protected. 14 Why the results of these latter studies disagree with our own is not clearly understood. Because previous studies suggest that adenosine signaling through the A 1 AR is responsible for activation of protein kinase C (PKC) 25, 26 and PKC is critically important for activation of CD73, 27 it is conceivable that A 1 AR signaling may result in PKC activation, which in turn activates CD73. In fact, we found that transcriptional induction of cd73 by IP was abolished after PKC inhibition or in A 1 AR Ϫ/Ϫ mice. Similarly, infarct size-limiting effects by IP were attenuated by PKC inhibition (Data Supplement Figure VI) . In conjunction with our findings that cardioprotection afforded by IP was less in A 1 AR Ϫ/Ϫ than in wild-type mice, it becomes possible that signaling through A 1 AR or ␣-adrenergic receptors 28 activates PKC, which in turn is responsible for CD73 activation, production of extracellular adenosine, and subsequent signaling through A 2B AR. In vitro studies have indicated a critical role of signaling through the A 2B AR in resealing of endothelia during transendothelial migration of neutrophils, particularly during conditions of limited oxygen availability. 2 Moreover, pharmacological inhibition of A 2B AR during hypoxia exposure is associated with increased pulmonary edema and vascular leakage. 6 Thus, the findings of the present study are consistent with previous work on adenosine signaling, transcriptional responses of A 2B AR after myocardial ischemia, and reperfusion, 12 as well as studies suggesting a cardioprotective role of A 2B AR during ischemic postconditioning, 29 but highlight for the first time a pivotal role of A 2B AR signaling in cardioprotection by IP.
At present, the source of extracellular adenosine generated during conditions of hypoxia or ischemia remains unknown. Previous reports have indicated that polymorphonuclear neutrophils release ATP during conditions of inflammation or hypoxia. 30 substrate for conversion to adenosine via ecto-apyrase (CD39, conversion of ATP/ADP to AMP) and ecto-5Ј-nucleotidase. Under such conditions, adenosine is available to activate ARs. Besides polymorphonuclear neutrophils, platelets may be an important source for extracellular ATP. 31 In addition, the exact cellular location of A 2B AR involved in cardioprotection by IP is currently unknown. As we show here, A 2B AR transcript levels and protein are induced in cardiac tissues by IP, suggesting a role of cardiac A 2B AR. However, a very carefully executed study on the role of A 2A AR signaling during myocardial ischemia suggested infarct size reduction by activation of A 2A AR on T lymphocytes. 32 Further studies are necessary to reveal which A 2B ARexpressing cells are responsible for the cardioprotective effects of IP.
In summary, the present study reveals cardioprotection during myocardial ischemia via CD73-dependent generation of extracellular adenosine and signaling through the A 2B AR. In fact, genetically targeted mice with deficiencies in the major extracellular pathway of adenosine generation (CD73) or in A 2B AR show increased susceptibility to acute myocardial ischemia and are not protected by IP. In addition, soluble 5Ј-nucleotidase or selective A 2B AR agonist treatment significantly attenuates infarct sizes after ischemia, suggesting possible new strategies to ameliorate the consequences of myocardial infarction. Future challenges include the development of approaches to deal with AR desensitization and delivery of AR agonists to specific anatomic sites. 
